VX-407 PK with Oral Contraceptives in Healthy Subjects

Phase 1, open-label trial of VX-407 in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of Oral Contraceptives and Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity of Oral Contraceptives. Started Jul 2025; status: completed.